Dyne Therapeutics (DYN)
Develops targeted genetic medicines for neuromuscular diseases through its FORCE delivery platform.
Something off on this page? Send us feedback.
Develops FORCE-platform therapeutics that carry oligonucleotide or enzyme payloads into muscle and the central nervous system. The pipeline is led by late-stage programs for Duchenne muscular dystrophy and myotonic dystrophy type 1; no product is approved, and manufacturing is outsourced.
Develops targeted therapies for genetically driven neuromuscular diseases using the FORCE platform, which couples a transferrin-receptor-targeting antibody fragment to oligonucleotide or enzyme payloads. The design aims to deliver medicines into skeletal, cardiac and smooth muscle and the central nervous system. Programs span Duchenne muscular dystrophy, myotonic dystrophy type 1, facioscapulohumeral muscular dystrophy and Pompe disease.
Lead programs are z-rostudirsen for exon-skipping-amenable Duchenne and z-basivarsen for myotonic dystrophy; both are in global late-stage development, and the former is under priority FDA review. The FSHD program has clearance to enter human testing, while the Pompe disease program remains preclinical. Commercial revenue depends on regulatory approval, and manufacturing is outsourced to contract organizations.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 9, 2026 | Morgan Stanley | Reiterate | Rating: —Target: $45 | Target: $36 |
| Sep 9, 2026 | RBC Capital | Reiterate | Rating: —Target: — | Target: $30 |
| Sep 9, 2026 | Robert W. Baird | Target | Target: $30 | Target: $26 |
| Sep 9, 2026 | JP Morgan | Downgrade | ||
| Sep 8, 2026 | Raymond James | Reiterate | Rating: —Target: $40 | Target: $37 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $898.5M · Total debt $19.9M · Total assets $994.0M · Shareholders' equity $702.2M
- Revenue
- $0
- Operating income
- −$181.7M
- Net income
- −$178.6M
No dividends on record.
| Institutions | 102.72% | 191.82M shares | |
|---|---|---|---|
| 254 holders · as of Jun 30, 2026 | |||
| Insiders | 2.53% | 4.72M shares | |
| 8 holders · as of Sep 8, 2026 | |||
| Strategic holders | 7.31% | 13.65M shares | |
| 1 holder · as of May 15, 2026 | |||
| Adds to | 112.56% | ||
186.75M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 112.56%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
T. Rowe Price Investment Management, Inc.Institution | 16.55% | 30.91M | as of Jun 30, 2026 |
Janus Henderson Group PLCStrategic | 7.31% | 13.65M | filed May 15, 2026 |
BlackRock, Inc.Institution | 6.64% | 12.40M | as of Jun 30, 2026 |
Jupiter Topco LLCInstitution | 6.42% | 12.00M | as of Jun 30, 2026 |
FMR LLCInstitution | 6.00% | 11.21M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 8, 2026 | John Cox | director, officer: CEO & President | −5,658 | $18.88 |
| Sep 8, 2026 | Douglas Kerr | officer: Chief Medical Officer | −1,290 | $18.88 |
| Sep 4, 2026 | Douglas Kerr | officer: Chief Medical Officer | −3,745 | $24.35 |
| Sep 8, 2026 | Johanna Friedl-Naderer | officer: Chief Commercial Officer | −185 | $18.88 |
| Sep 4, 2026 | Johanna Friedl-Naderer | officer: Chief Commercial Officer | −900 | $24.35 |
- Atrium Therapeutics
TfR1 full-antibody-conjugate platform in DM1, DMD exon 44, and FSHD
- Sarepta Therapeutics
Approved PMO triplet and micro-dystrophin gene therapy hold dominant DMD market
- REGENXBIO
Pivotal DMD gene therapy (RGX-202) targeting accelerated FDA approval in 2027
- PepGen
EDO-platform DM1 oligonucleotide in Phase 2; DMD program discontinued May 2025
- Solid Biosciences
Next-gen microdystrophin gene therapy (SGT-003) in pivotal Phase 3 trial
- BioMarin
Rare-disease biotech with Pompe ERT franchise and DMD exon-51 ASO in Phase 1/2
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Dyne Therapeutics | $16.59 | −3.20% | $3.20B | — | — | — | — |
| Atrium Therapeutics | $8.71 | −5.53% | $157.7M | — | — | 6.7 | — |
| Sarepta Therapeutics | $19.40 | −6.80% | $2.20B | — | 33.7 | 1.1 | −34.3% |
| REGENXBIO | $7.73 | −5.15% | $421.3M | — | — | 2.4 | +405.7% |
| PepGen | $2.79 | −6.54% | $206.1M | — | — | — | — |
| Solid Biosciences | $8.39 | −6.00% | $878.2M | — | — | — | — |
| BioMarin | $62.09 | −2.02% | $12.25B | 162.5 | 10.1 | 3.6 | +20.0% |
| Median | 162.5 | 21.9 | 3.0 | +20.0% |